FGFR3; ACH; CEK2; JTK4; CD333; HSFGFR3EX; Fibroblast growth factor receptor 3; FGFR-3; fibroblast growth factor receptor 3

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

FGFR3 antibody is human, mouse and rat reactive. At least three isoforms of FGFR3 are known to exist; this antibody will detect all three.

FGFR3 Antibody is affinity chromatography purified via peptide column.

Liquid

1 mg/mL (lot specific)

FGFR3 antibody can be stored at 4 degree C for three months and -20 degree C, stable for up to one year.

Small volumes of anti-FGFR3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

FGFR3 Antibody: FGFR3 is a tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis (1). It is required for normal skeleton development and promotes apoptosis in chondrocytes and cancer cell proliferation. FGFR3 protein contains three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain (1,2). It is alternatively spliced to produce three isoforms that are expressed in brain, kidney and testis. Defects in FGFR3 are associated with several diseases, including achondroplasia and hypochondroplasia (3,4). Mutations in FGFR3 are also a cause of some bladder and cervical cancers (5).

ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

FGF3 antibody can be used for detection of FGFR3 by Western blot at 1 - 2 mug/mL.

Western blot analysis of FGFR3 in SK-N-SH cell lysate with FGFR3 antibody at (A) 0.5 and (B) 1 μg/mL.

Immunohistochemistry of FGFR3 in rat brain tissue with FGFR3 antibody at 2.5 μg/mL.

Immunofluorescence of FGFR3 in rat brain tissue with FGFR3 antibody at 20 μg/mL.

Predicted: 89 kDa

Observed: 9+2; 98 kDa

fibroblast growth factor receptor 3

fibroblast growth factor receptor 3; FGFR-3; tyrosine kinase JTK4; hydroxyaryl-protein kinase; fibroblast growth factor receptor 3 variant 4

Fibroblast growth factor receptor 3

JTK4; FGFR-3??[Similar Products]

FGFR3_HUMAN

This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq, Jul 2009]

FGFR3: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer.

Protein type: Protein kinase, TK; Protein kinase, tyrosine (receptor); Membrane protein, integral; Kinase, protein; EC 2.7.10.1; TK group; FGFR family

Chromosomal Location of Human Ortholog: 4p16.3

Cellular Component: Golgi apparatus; transport vesicle; internal side of plasma membrane; focal adhesion; cell surface; endoplasmic reticulum; perinuclear region of cytoplasm; integral to plasma membrane; lysosome; extracellular region; plasma membrane; nucleus

Molecular Function: protein binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; protein-tyrosine kinase activity; ATP binding

Biological Process: peptidyl-tyrosine phosphorylation; nerve growth factor receptor signaling pathway; somatic stem cell maintenance; protein amino acid autophosphorylation; negative regulation of transcription from RNA polymerase II promoter; bone mineralization; positive regulation of tyrosine phosphorylation of Stat3 protein; substantia nigra development; inner ear receptor cell differentiation; cell-cell signaling; positive regulation of MAPKKK cascade; positive regulation of neuron apoptosis; positive regulation of cell proliferation; forebrain development; morphogenesis of an epithelium; chondrocyte differentiation; response to axon injury; skeletal development; endochondral ossification; negative regulation of epithelial cell proliferation; negative regulation of developmental growth; epidermal growth factor receptor signaling pathway; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; myelination in the central nervous system; MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; digestive tract morphogenesis; JAK-STAT cascade; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of protein ubiquitination; negative regulation of smoothened signaling pathway; negative regulation of mitosis; negative regulation of astrocyte differentiation; insulin receptor signaling pathway; innate immune response; lens morphogenesis in camera-type eye; positive regulation of endothelial cell proliferation; positive regulation of cell differentiation

Disease: Bladder Cancer; Lacrimoauriculodentodigital Syndrome; Camptodactyly, Tall Stature, And Hearing Loss Syndrome; Achondroplasia; Hypochondroplasia; Muenke Syndrome; Thanatophoric Dysplasia, Type Ii; Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans; Cervical Cancer; Thanatophoric Dysplasia, Type I; Crouzon Syndrome With Acanthosis Nigricans; Colorectal Cancer; Testicular Germ Cell Tumor; Nevus, Epidermal

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.